Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perseus Proteomics, Inc. has presented an interim report for the first phase of clinical trials for their drug PPMX-T003, targeting polycythemia vera, at the 14th JSH International Symposium. The report, presented by Dr. Tadashi Matsuura, highlighted the drug’s safety and efficacy, with data from five patients confirming its primary and secondary evaluation goals.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.